Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Search
Using AI to transform screening for type 2 diabetes
Using AI to transform screening for type 2 diabetes
COACH Program
The COACH Program addresses the unique needs of people living with heart failur and it's yielding promising results across Ontario. Find out more.
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Collaboration key to meeting consumers’ expectations for better animal welfare
Collaboration key to meeting consumers’ expectations for better animal welfare
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New data showed OFEV® (nintedanib) slows decline of lung function in broad range of chronic fibrosing interstitial lung diseases with a progressive phenotype
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
New data presented at the American Thoracic Society Conference showed nintedanib slows loss of pulmonary function in people living with systemic sclerosis associated ILD
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Inadvertent self-injection: The risk associated with oil-based vaccines
Inadvertent self-injection: The risk associated with oil-based vaccines
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
New data presented at the ISTH 2015 Congress show Idarucizumab* results in immediate reversal of dabigatran in patients requiring urgent medical procedures or with serious bleeding complications1,2
Accessibility Statement
Accessability Statement
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
Ingelvac CircoFLEX®: The most successful animal health vaccine of all time is also a very versatile product
AHEAD Program
The partnership program led by Boehringer Ingelheim Canada to address gaps in Canada’s health system for people living with T2D and heart failure. Click to read more.
Does your PRRS vaccine have sufficient “horsepower?”
Does your PRRS vaccine have sufficient “horsepower?”
INSPIRED
Read more about INSPIRED, aimed at expanding a hospital-to-home program to better support people living with chronic obstructive pulmonary disease (COPD).
CONTINUUM
CONTINUUM, a collaborative project, investigates how digital technology can help healthcare professionals manage complex patient cases at home. Keep reading.
Home Health Monitoring
Read more about the HHM Project that provides a community-based home health monitoring digital solution for people living with chronic conditions.
Machine learning for patients
Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.
More Green
More Green